Dr. Girish Kulkarni, MD
Claim this profileUniversity Health Network
Studies Bladder Cancer
Studies Non-Muscle Invasive Bladder Cancer
2 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Girish Kulkarni, MD is currently running
PDT
for Bladder Cancer
This trial tests a new treatment for bladder cancer patients who do not respond to or cannot tolerate standard therapy. The treatment uses a drug called Ruvidar® that is activated by a special light to kill cancer cells in the bladder.
Recruiting1 award Phase 210 criteria
Chemotherapy
for Bladder Cancer
Upper tract urothelial cancer (UTUC) is cancer in the lining of the kidney or ureter (the tube that drains the kidney). This type of cancer is rare and as a result, there are only a few studies that have looked at it. Standard of care for UTUC would be surgery followed by chemotherapy (adjuvant chemotherapy). However, we know from studies that have looked at cancer of the lining of the bladder, which is a similar cancer in many ways, that treating people with chemotherapy before surgery (neoadjuvant chemotherapy) can lead to longer survival compared to the standard of care. There are no studies to show this in UTUC. Neoadjuvant chemotherapy is thought to help improve survival by treating any cancer that may have spread from the original tumour but that is not visible yet on scans. This study would be the first clinical trial in Canada to evaluate the use of chemotherapy before surgery in this disease setting. Since UTUC is rare, the purpose of this study is to determine if it is possible to enrol enough patients to a trial looking at the use of chemotherapy before surgery.
Recruiting2 awards Phase 3
More about Girish Kulkarni, MD
Clinical Trial Related5 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Girish Kulkarni, MD has experience with
- Ruvidar® (TLD-1433)
- Carboplatin
- Cisplatin
- Gemcitabine
Breakdown of trials Girish Kulkarni, MD has run
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Transitional Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Girish Kulkarni, MD specialize in?
Girish Kulkarni, MD focuses on Bladder Cancer and Non-Muscle Invasive Bladder Cancer. In particular, much of their work with Bladder Cancer has involved treating patients, or patients who are undergoing treatment.
Is Girish Kulkarni, MD currently recruiting for clinical trials?
Yes, Girish Kulkarni, MD is currently recruiting for 2 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Girish Kulkarni, MD has studied deeply?
Yes, Girish Kulkarni, MD has studied treatments such as Ruvidar® (TLD-1433), Carboplatin, Cisplatin.
What is the best way to schedule an appointment with Girish Kulkarni, MD?
Apply for one of the trials that Girish Kulkarni, MD is conducting.
What is the office address of Girish Kulkarni, MD?
The office of Girish Kulkarni, MD is located at: University Health Network, Toronto, Ontario M5G2M9 Canada. This is the address for their practice at the University Health Network.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.